Mental Health DailyResearch. Evidence. Perspective.Published research on discontinuation.
The rise in antidepressant prescribing, especially selective serotonin reuptake inhibitors (SSRIs) since the 1980s, is a complex phenomenon with broad implications for public health. While t…
Read articleFetzima (Levomilnacipran), is a serotonin-norepinephrine reuptake inhibitor (SNRI) that was approved by the United States FDA in 2013 for the treatment of major depressive disorder. It was e…
Read articleRexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adju…
Read articleTianeptine, also referred to under the brand names “Stablon” and “Coaxil,” is an antidepressant originally discovered and patented in the 1960s by the French Society of Medical Research. The…
Read articleFanapt (Iloperidone) is an atypical antipsychotic that was approved by the FDA on May 6, 2009 for the treatment of schizophrenia. The drug is thought to have been synthesized in the 1990s, d…
Read articleIt appears as though the pharmaceutical juggernaut Eli Lilly is facing major legal backlash for failure to disclose discontinuation effects associated with their medication Cymbalta (Duloxet…
Read article